Home page Home page

Multaq
dronedarone

Package leaflet: Information for the patient


MULTAQ 400 mg film-coated tablets

dronedarone


Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

Warnings and precautions

Talk to your doctor or pharmacist before taking MULTAQ if

atorvastatin, or rosuvastatin),


Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.


  1. How to store MULTAQ


    Keep this medicine out of the sight and reach of children.


    Do not use this medicine after the expiry date, which is stated on the blister and carton after “EXP.” The expiry date refers to the last day of that month.

    This medicinal product does not require any special storage conditions.


    Do not use this medicine if you notice any visible sign of deterioration (see section 6).


    Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.


  2. Contents of the pack and other information What MULTAQ contains


What MULTAQ looks like and content of the pack

MULTAQ is a white, oval, film-coated tablet (tablet) with a double wave marking on one side and “4142” on the other side.


MULTAQ film-coated tablets are supplied in packs of 20, 50, 60 tablets in opaque PVC and aluminium blisters and 100x1 tablets in opaque PVC and aluminium perforated unit dose blisters. Not all pack size may be marketed.


Marketing Authorisation Holder

sanofi-aventis groupe 54, rue La Boétie

F-75008 Paris – France


Manufacturer

Sanofi Winthrop Industrie

1 rue de la Vierge, Ambarès & Lagrave, F-33565 Carbon Blanc Cedex - France


Sanofi-Aventis Deutschland GmbH Brüningstrasse 50

Industriepark Höchst, D-65926 Frankfurt

Germany


image

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.


België/Belgique/Belgien

Sanofi Belgium

Tél/Tel: +32 (0)2 710 54 00

Lietuva

Swixx Biopharma UAB Tel: +370 5 236 91 40


България

Swixx Biopharma EOOD

Тел.: +359 (0)2 4942 480

Luxembourg/Luxemburg

Sanofi Belgium

Tél/Tel: +32 (0)2 710 54 00 (Belgique/Belgien)

Česká republika sanofi-aventis, s.r.o. Tel: +420 233 086 111

Magyarország

SANOFI-AVENTIS Zrt. Tel.: +36 1 505 0050


Danmark

Sanofi A/S

Tlf: +45 45 16 70 00

Malta

Sanofi S.r.l.

Tel: +39 02 39394275


Deutschland

Sanofi-Aventis Deutschland GmbH Tel.: 0800 52 52 010

Tel. aus dem Ausland: +49 69 305 21 131

Nederland

Genzyme Europe B.V. Tel: +31 20 245 4000


Eesti

Swixx Biopharma OÜ Tel: +372 640 10 30

Norge

sanofi-aventis Norge AS Tlf: +47 67 10 71 00


Ελλάδα

sanofi-aventis AEBE

Τηλ: +30 210 900 16 00

Österreich

sanofi-aventis GmbH Tel: +43 1 80 185 – 0


España

sanofi-aventis, S.A. Tel: +34 93 485 94 00

Polska

sanofi-aventis Sp. z o.o. Tel.: +48 22 280 00 00


France

sanofi-aventis France Tél: 0 800 222 555

Appel depuis l’étranger : +33 1 57 63 23 23


Hrvatska

Swixx Biopharma d.o.o. Tel: +385 1 2078 500

Portugal

Sanofi - Produtos Farmacêuticos, Lda. Tel: +351 21 35 89 400


România

Sanofi Romania SRL Tel: +40 (0) 21 317 31 36


Ireland

sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +353 (0) 1 403 56 00

Slovenija

Swixx Biopharma d.o.o. Tel: +386 1 235 51 00


Ísland

Vistor hf.

Sími: +354 535 7000

Slovenská republika Swixx Biopharma s.r.o. Tel: +421 2 208 33 600


Italia

Sanofi S.r.l. Tel: 800.536389

Suomi/Finland

Sanofi Oy

Puh/Tel: +358 (0) 201 200 300


Κύπρος

C.A. Papaellinas Ltd.

Τηλ: +357 22 741741

Sverige

Sanofi AB

Tel: +46 (0)8 634 50 00


Latvija

Swixx Biopharma SIA Tel: +371 6 616 47 50

United Kingdom (Northern Ireland) sanofi-aventis Ireland Ltd. T/A SANOFI Tel: +44 (0) 800 035 2525


This leaflet was last revised in

image

.